Tebentafusp for advanced eye melanoma
Treatments studied
Part of Cancer, Eyes & vision, Skin clinical trials.
This trial provides access to tebentafusp, a treatment for advanced melanoma of the eye that cannot be removed by surgery. It may help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of eye melanoma that has spread or cannot be removed surgically.
- You have a specific genetic marker called HLA-A*02:01.
- You are generally able to care for yourself (ECOG performance status 0 or 1).
- You have not had certain cancer treatments recently, and you do not have untreated or active brain metastases.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called tebentafusp given after standard treatment (surgery or radiation) for high-risk uveal melanoma that hasn't spread. The goal is to see if it helps prevent the cancer from coming back.
This trial tests a new drug called tebentafusp for people with uveal melanoma that has spread to other parts of the body and who have not yet received any treatment for the metastatic disease. It requires a specific genetic marker (HLA-A*0201) and focuses on whether the drug can shrink or slow the growth of tumors.
This trial tests if adding another drug called IL-2 to tebentafusp can help stop cancer from growing in people with advanced melanoma that started in the eye (uveal melanoma). It is for those whose cancer got worse while on tebentafusp alone.
This trial tests a new drug (RBP-01) given before standard treatment for uveal melanoma, a type of eye cancer. The goal is to see if the drug can shrink the tumor or improve outcomes for people who need eye removal or high-risk radiation therapy.
This trial tests a drug called Tebentafusp for a type of eye melanoma (uveal melanoma) that is too large to be removed without taking out the whole eye. The goal is to see if the drug can shrink the tumor before deciding on surgery.
This Phase 3 study compares tebentafusp treatment against the doctor’s choice of standard options in people with previously treated advanced melanoma. It aims to see which approach works better for controlling the cancer and improving outcomes.
Hear when a new Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.